WCO-IOF-ESCEO took place between 4-7 May and brought all of the latest clinical findings and advances in osteoporosis, osteoarthritis and musculoskeletal diseases. We were delighted to talk with Editorial Board member Prof. Nicholas Fuggle (MRC Life Force Epidemiology Centre, University of Southampton, UK) around his personal highlights from this year’s conference and the most promising […]

touchIMMUNOLOGY spoke with editorial board member Alessia Alunno (University of L’Aquila, Italy) to discuss her highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of Sjögren’s syndrome, and summarize the main take-home messages from her presentation. The abstract ‘COVID-19 severity and vaccine breakthrough infections in Sjögren’s syndrome: results from the […]

The COLOR trial is a  single-centre, double-blind, randomised, placebo-controlled trial that aimed to investigate colchicine’s efficacy and safety compared with placebo in people with hand osteoarthritis. touchIMMUNOLOGY were delighted to speak with Dr Anna Døssing (The Parker Institute, University of Copenhagen Copenhagen, Denmark) about the findings of the COLOR trial and what further investigation is […]

touchIMMUNOLOGY spoke with editorial board member Jérôme Avouac (Hôpital Cochin, Paris, France) to discuss his highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of rheumatoid arthritis, and his presentation on the potential of CD19-targeted CAR-T cell transfer for systemic sclerosis. The abstract ‘Effects of B cell depletion by […]

International experts from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have recently partnered to produce the much-anticipated classification criteria for antiphospholipid syndrome (APS), which were published in Arthritis & Rheumatology in August 2023.1 Prior to the publication of the new ACR/EULAR APS classification criteria, research studies used the Sapporo criteria, […]

It is increasingly recognized that autoimmune rheumatic diseases (ARDs) can affect people of any age, starting from early childhood and continuing until later in life. Furthermore, in recent decades, it has become apparent that Sjögren disease (SjD), commonly diagnosed in women aged 35–50 years old, can also affect men of all ages, as well as […]

This editorial outlines a clinical approach to patients with periodic inflammation of unknown origin despite initial rational and targeted investigation. The focus of the editorial is on the recognition and diagnosis of systemic autoinflammatory diseases (SAIDs). Although rare, SAIDs are valuable diagnoses given they carry a risk of disease-associated damage and are often treatable. The authors […]

The global burden of disease is heavily impacted by the increased prevalence of chronic inflammatory rheumatic diseases (CIRDs [rheumatoid arthritis (RA), spondyloarthritis (SpA), connective tissue diseases (CTDs) crystal arthropathies and polyarticular osteoarthritis (OA)]), which are prevalent chronic non-communicable diseases associated with pain, functional impairment, and years lived with disability (YLDs).1–4 Comorbidities associated with CIRDs contribute […]